In summary, although current research on the targeting of BGN mainly focuses on folate modification, these studies not only demonstrate the feasibility and effectiveness of BGN as a targeted drug carrier, but also lay a solid foundation for the development of more diverse and efficient tumor treatment plans in the future. This evidence concerns the gene BGN and neoplasm.